Do analysts prefer SCYX or COCP?

SCYNEXIS currently has a consensus target price of $24.00, suggesting a potential upside of 395.87%. Given SCYNEXIS's stronger consensus rating and higher possible upside, equities analysts clearly believe SCYNEXIS is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate INCR or COCP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is INCR or COCP more profitable?

InterCure's return on equity of 0.00% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Cocrystal Pharma N/A -150.61% -97.86%

Do analysts recommend COCP or FLNA?

Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 414.62%. Given Cassava Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, COCP or FLNA?

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.73 N/A Cassava Sciences N/A N/A -$90.97M -$0.87 N/A

Is COCP or FLNA more profitable?

Cassava Sciences' return on equity of -58.78% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% Cassava Sciences N/A -58.78% -36.74%

Do analysts recommend CPHI or COCP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer COCP or KPTI?

Karyopharm Therapeutics has a consensus target price of $11.50, indicating a potential upside of 447.62%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Karyopharm Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57

Cocrystal Pharma (COCP) Competitors

$1.08 0.00 (0.00%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$1.10 +0.02 (+1.76%)

As of 08/11/2026 05:17 PM Eastern

Compare

COCP vs. SCYX, INCR, FLNA, CPHI, and KPTI

Should you buy Cocrystal Pharma stock or one of its competitors? Cocrystal Pharma's main competitors and comparable companies include SCYNEXIS (SCYX), InterCure (INCR), Cassava Sciences (FLNA), China Pharma (CPHI), and Karyopharm Therapeutics (KPTI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cocrystal Pharma compare to SCYNEXIS?

SCYNEXIS (NASDAQ:SCYX) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Cocrystal Pharma has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -50.54% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-50.54%	-34.22%
Cocrystal Pharma	N/A	-150.61%	-97.86%

SCYNEXIS has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.33	-$8.61M	-$3.84	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A

54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 4.1% of SCYNEXIS shares are owned by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, SCYNEXIS had 5 more articles in the media than Cocrystal Pharma. MarketBeat recorded 7 mentions for SCYNEXIS and 2 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 1.44 beat SCYNEXIS's score of 0.87 indicating that Cocrystal Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
SCYNEXIS	Positive
Cocrystal Pharma	Positive

SCYNEXIS currently has a consensus target price of $24.00, suggesting a potential upside of 395.87%. Given SCYNEXIS's stronger consensus rating and higher possible upside, equities analysts clearly believe SCYNEXIS is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SCYNEXIS has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

Summary

SCYNEXIS beats Cocrystal Pharma on 9 of the 15 factors compared between the two stocks.

How does Cocrystal Pharma compare to InterCure?

InterCure (NASDAQ:INCR) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Cocrystal Pharma has lower revenue, but higher earnings than InterCure. Cocrystal Pharma is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.68	-$10.37M	$0.03	32.60
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A

InterCure has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

InterCure's return on equity of 0.00% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Cocrystal Pharma	N/A	-150.61%	-97.86%

In the previous week, InterCure and InterCure both had 2 articles in the media. Cocrystal Pharma's average media sentiment score of 1.44 beat InterCure's score of 0.93 indicating that Cocrystal Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Positive
Cocrystal Pharma	Positive

8.3% of InterCure shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 39.4% of Cocrystal Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

InterCure beats Cocrystal Pharma on 6 of the 10 factors compared between the two stocks.

How does Cocrystal Pharma compare to Cassava Sciences?

Cocrystal Pharma (NASDAQ:COCP) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cassava Sciences' return on equity of -58.78% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Cassava Sciences	N/A	-58.78%	-36.74%

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

In the previous week, Cocrystal Pharma had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 2 mentions for Cocrystal Pharma and 1 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 1.87 beat Cocrystal Pharma's score of 1.44 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Cocrystal Pharma	Positive
Cassava Sciences	Very Positive

Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 414.62%. Given Cassava Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cocrystal Pharma has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.7, meaning that its share price is 170% less volatile than the broader market.

Summary

Cassava Sciences beats Cocrystal Pharma on 8 of the 13 factors compared between the two stocks.

How does Cocrystal Pharma compare to China Pharma?

China Pharma (NYSE:CPHI) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Cocrystal Pharma has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Cocrystal Pharma	N/A	-150.61%	-97.86%

6.7% of Cocrystal Pharma shares are held by institutional investors. 6.4% of China Pharma shares are held by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

China Pharma has higher revenue and earnings than Cocrystal Pharma. China Pharma is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	11.47	-$3.08M	-$0.55	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A

In the previous week, Cocrystal Pharma had 2 more articles in the media than China Pharma. MarketBeat recorded 2 mentions for Cocrystal Pharma and 0 mentions for China Pharma. Cocrystal Pharma's average media sentiment score of 1.44 beat China Pharma's score of 0.00 indicating that Cocrystal Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
China Pharma	Neutral
Cocrystal Pharma	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

China Pharma has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

Summary

Cocrystal Pharma beats China Pharma on 8 of the 13 factors compared between the two stocks.

How does Cocrystal Pharma compare to Karyopharm Therapeutics?

Cocrystal Pharma (NASDAQ:COCP) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Cocrystal Pharma has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

6.7% of Cocrystal Pharma shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 39.4% of Cocrystal Pharma shares are held by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Karyopharm Therapeutics had 5 more articles in the media than Cocrystal Pharma. MarketBeat recorded 7 mentions for Karyopharm Therapeutics and 2 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 1.44 beat Karyopharm Therapeutics' score of 0.15 indicating that Cocrystal Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Cocrystal Pharma	Positive
Karyopharm Therapeutics	Neutral

Cocrystal Pharma has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Karyopharm Therapeutics has a consensus target price of $11.50, indicating a potential upside of 447.62%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Cocrystal Pharma has higher earnings, but lower revenue than Karyopharm Therapeutics. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
Karyopharm Therapeutics	$146.07M	0.33	-$196.04M	-$15.09	N/A

Summary

Karyopharm Therapeutics beats Cocrystal Pharma on 9 of the 16 factors compared between the two stocks.

Get Cocrystal Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COCP vs. The Competition

Export

Metric	Cocrystal Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.89M	$12.02B	$7.08B	$12.96B
Dividend Yield	N/A	2.69%	2.57%	10.34%
P/E Ratio	-1.48	783.52	268.40	25.05
Price / Sales	N/A	749.62	558.69	69.51
Price / Cash	N/A	70.00	72.26	50.42
Price / Book	2.35	10.56	13.21	6.18
Net Income	-$8.83M	$2.78B	$3.44B	$347.05M
7 Day Performance	5.88%	0.52%	2.07%	1.24%
1 Month Performance	6.93%	-1.50%	-0.26%	-0.65%
1 Year Performance	-34.55%	165.83%	70.32%	20.12%

Cocrystal Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COCP Cocrystal Pharma	1.45 of 5 stars	$1.08 flat	N/A	-32.5%	$14.89M	N/A	N/A	10	Positive News Upcoming Earnings
SCYX SCYNEXIS	3.6679 of 5 stars	$5.40 +6.5%	$24.00 +344.4%	-31.3%	$53.62M	$20.34M	N/A	60	Earnings Report
INCR InterCure	0.91 of 5 stars	$0.96 +1.0%	N/A	-42.1%	$52.65M	$78.47M	32.10	350	News Coverage Gap Down
FLNA Cassava Sciences	2.1778 of 5 stars	$1.00 -3.3%	$5.00 +401.8%	-56.8%	$48.14M	N/A	N/A	20	Positive News
CPHI China Pharma	N/A	$1.18 +3.5%	N/A	-16.3%	$47.82M	$3.99M	N/A	250

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COCP) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cocrystal Pharma (COCP) Competitors

COCP vs. SCYX, INCR, FLNA, CPHI, and KPTI

How does Cocrystal Pharma compare to SCYNEXIS?

Summary

How does Cocrystal Pharma compare to InterCure?

Summary

How does Cocrystal Pharma compare to Cassava Sciences?

Summary

How does Cocrystal Pharma compare to China Pharma?

Summary

How does Cocrystal Pharma compare to Karyopharm Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cocrystal Pharma (COCP) Competitors

COCP vs. SCYX, INCR, FLNA, CPHI, and KPTI

How does Cocrystal Pharma compare to SCYNEXIS?

Is SCYX or COCP more profitable?

Which has stronger valuation & earnings, SCYX or COCP?

Do insiders and institutionals hold more shares of SCYX or COCP?

Does the media favor SCYX or COCP?

Do analysts prefer SCYX or COCP?

Which has more volatility and risk, SCYX or COCP?

Summary

How does Cocrystal Pharma compare to InterCure?

Which has higher valuation and earnings, INCR or COCP?

Which has more risk & volatility, INCR or COCP?

Do analysts rate INCR or COCP?

Is INCR or COCP more profitable?

Does the media favor INCR or COCP?

Do insiders and institutionals have more ownership in INCR or COCP?

Summary

How does Cocrystal Pharma compare to Cassava Sciences?

Do institutionals & insiders have more ownership in COCP or FLNA?

Is COCP or FLNA more profitable?

Which has preferable earnings & valuation, COCP or FLNA?

Does the media prefer COCP or FLNA?

Do analysts recommend COCP or FLNA?

Which has more risk & volatility, COCP or FLNA?

Summary

How does Cocrystal Pharma compare to China Pharma?

Is CPHI or COCP more profitable?

Do insiders and institutionals have more ownership in CPHI or COCP?

Which has better earnings and valuation, CPHI or COCP?

Does the media favor CPHI or COCP?

Do analysts recommend CPHI or COCP?

Which has more volatility and risk, CPHI or COCP?

Summary

How does Cocrystal Pharma compare to Karyopharm Therapeutics?

Which has more volatility and risk, COCP or KPTI?

Do institutionals & insiders have more ownership in COCP or KPTI?

Does the media prefer COCP or KPTI?

Is COCP or KPTI more profitable?

Do analysts prefer COCP or KPTI?

Which has preferable valuation & earnings, COCP or KPTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools